Table 1.
Baseline characteristics of included trials
| First author/year | Treatment arms | No of patients, n | Age, years (range) | ECOG PS, n (%)
|
HR-positive tumors, n (%) | Prior (neo)adjuvant CT, n (%)
|
No of metastaticsites, n (%) | Outcome measures | Jadad scores | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | Taxane | Anthracycline | ||||||||
| Mayer et al12 2010 | P 90 mg/m2 days 1, 8. 15 + B 10 mg/m2 days 1, 15 q4w | 23 | 52 (29–80) | 12 (52) | 11 (48) | 0 | 18 (78) | NR | NR | NR | AEs | 2 |
| P 90 mg/m2 days 1, 8. 15 + B 10 mg/m2 days 1, 15 + Sun 37.5 mg/m2 daily for 21 days q4w | 23 | 58 (34–81) | 11 (50) | 11 (50) | 0 | 17 (74) | NR | NR | NR | |||
| Brufsky et al13 2011 | P 90 mg/m2 days 1, 8. 15 + B 10 mg/m2 days 1, 15 q4w | 94 | 57.5 (30.8–83.8) | 57 (60.6) | 37 (39.4) | 0 | ER: 60 (63.8) PR: 42 (44.7) |
33 (35.1) | NR | NR | ORR, PFS, OS, AEs | 3 |
| P 90 mg/m2 days 1, 8. 15 + B 10 mg/m2 days 1, 15 + Gem 1,500 mg/m2 days 1, 15 q4w | 93 | 55.2 (37.1–79.7) | 60 (64.5) | 31 (33.3) | 0 | ER: 67 (73) PR: 57 (61.3) |
32 (34.4) | NR | NR | |||
| Lam et al14 2014 | P 90 mg/m2 days 1, 8. 15 + B 10 mg/m2 days 1, 15 q4w | 156 | 56 (34–74) | 81 (52) | 75 (48) | 0 | 132 (85) | NR | 81 (52) | <3: 80 (51); ≥3: 76 (49) | ORR, PFS, OS, AEs | 3 |
| P 90 mg/m2 days 1, 8 + B 15 mg/m2 day 1 + Cap 825 mg/m2 twice daily on days 1–14 q3w | 156 | 56 (32–76) | 82 (53) | 74 (47) | 0 | 133 (85) | NR | 78 (50) | <3: 94 (60); ≧3: 61 (39) | |||
| Lück et al15 2015 | D 75 mg/m2 day 1 or P 80 mg/m2 days 1, 8. 15 + B 15 mg/m2 day 1 q4w | 116 | 57 (33–80) | 83 (72.2) | 29 (25.2) | 3 (2.6) | 90 (77.6) | NR | NR | ≤3: 99 (85.3); >3: 17 (14.7) | ORR, PFS, | 3 |
| D 75 mg/m2 day 1 or P 80 mg/m2 days 1, 8. 15 + B 15 mg/m2 day 1 + Cap 1,800 mg/m2 days 1–14 q4w | 111 | 57 (31–78) | 87 (78.4) | 18 (16.2) | 6 (5.4) | 86 (77.5) | NR | NR | ≦3: 92 (82.9); >3: 19 (17.1) | |||
| Diéras et al16 2015 | P 90 mg/m2 days 1, 8. 15 + B 10 mg/m2 days 1, 15 q4w | 62 | 51.5 (37–69) | 37 (59.7) | 25 (40.3) | 0 | NR | NR | NR | <3: 35 (56.5); ≧3: 27 (43.5) | ORR, PFS, OS, AEs | 5 |
| P 90 mg/m2 days 1, 8. 15 + B 10 mg/m2 days 1, 15 + Ona 10 mg/kg days 1, 15 q4w | 63 | 53 (35–79) | 35 (55.6) | 28 (44.4) | 0 | NR | NR | NR | <3: 36 (57.1); ≧3: 27 (42.9) | |||
| Diéras et al17 2015 | P 90 mg/m2 days 1, 8. 15 + B 10 mg/m2 days 1, 15 + placebo q4w | 56 | 51.5 (31–74) | 60 | 40 | 0 | 45 (78) | 11 (19) | NR | ≦3: 79; >3: 21 | ORR, PFS, AEs | 5 |
| P 90 mg/m2 days 1, 8. 15 + B 10 mg/m2 days 1, 15 + Tre 10 mg/kg once a week q4w | 58 | 56.5 (32–75) | 61 | 38 | 2 | 45 (80) | 10 (18) | NR | ≦3: 79; >3: 21 | |||
| Yardley et al18 2015 | P 90 mg/m2 days 1, 8. 15 + B 10 mg/m2 days 1, 15 q4w | 57 | 57 (25–79) | NR | NR | NR | 45 (79) | 19 (33) | 6 (10) | <3: 23 (41); ≧3: 34 (59) | ORR, PFS, OS, AEs | 5 |
| P 90 mg/m2 days 1, 8. 15 + B 10 mg/m2 days 1, 15 + Eve 10 mg, once daily on day 1 q4w | 56 | 61 (30–77) | NR | NR | NR | 44 (79) | 24 (43) | 4 (7) | <3: 28 (550); ≧3: 28 (50) | |||
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; HR, hormone receptor; CT, chemotherapy; P, paclitaxel; B, bevacizumab; NR, no report; Sun, sunitinib; AEs, adverse events; ER, estrogen receptor; PR, progesterone receptor; Gem, gemcitabine; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; Cap, capecitabine; D, docetaxel; Ona, onartuzumab; Tre, trebananib; Eve, everolimus.